BIOGEN INC (IDP.DE) Fundamental Analysis & Valuation
FRA:IDP • US09062X1037
165.1 EUR
+2.55 (+1.57%)
Last: Mar 11, 2026, 07:00 PM
This IDP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
We assign a fundamental rating of 5 out of 10 to IDP. IDP was compared to 83 industry peers in the Biotechnology industry. IDP is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IDP is cheap, but on the other hand it scores bad on growth. This makes IDP very considerable for value investing!
1. IDP.DE Profitability Analysis
1.1 Basic Checks
- IDP had positive earnings in the past year.
- In the past year IDP had a positive cash flow from operations.
- IDP had positive earnings in each of the past 5 years.
- In the past 5 years IDP always reported a positive cash flow from operatings.
1.2 Ratios
- With a decent Return On Assets value of 4.39%, IDP is doing good in the industry, outperforming 75.90% of the companies in the same industry.
- IDP has a Return On Equity of 7.08%. This is in the better half of the industry: IDP outperforms 77.11% of its industry peers.
- IDP has a better Return On Invested Capital (8.93%) than 78.31% of its industry peers.
- IDP had an Average Return On Invested Capital over the past 3 years of 8.93%. This is below the industry average of 12.16%.
- The 3 year average ROIC (8.93%) for IDP is below the current ROIC(8.93%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.39% | ||
| ROE | 7.08% | ||
| ROIC | 8.93% |
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
1.3 Margins
- IDP has a Profit Margin of 13.07%. This is in the better half of the industry: IDP outperforms 77.11% of its industry peers.
- In the last couple of years the Profit Margin of IDP has declined.
- With an excellent Operating Margin value of 27.94%, IDP belongs to the best of the industry, outperforming 81.93% of the companies in the same industry.
- IDP's Operating Margin has declined in the last couple of years.
- IDP has a Gross Margin of 75.69%. This is in the better half of the industry: IDP outperforms 63.86% of its industry peers.
- In the last couple of years the Gross Margin of IDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.94% | ||
| PM (TTM) | 13.07% | ||
| GM | 75.69% |
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
2. IDP.DE Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IDP is still creating some value.
- Compared to 1 year ago, IDP has more shares outstanding
- The number of shares outstanding for IDP has been reduced compared to 5 years ago.
- IDP has a better debt/assets ratio than last year.
2.2 Solvency
- IDP has an Altman-Z score of 3.34. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of IDP (3.34) is better than 66.27% of its industry peers.
- IDP has a debt to FCF ratio of 3.11. This is a good value and a sign of high solvency as IDP would need 3.11 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 3.11, IDP belongs to the best of the industry, outperforming 83.13% of the companies in the same industry.
- IDP has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
- IDP has a Debt to Equity ratio (0.34) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | 3.11 | ||
| Altman-Z | 3.34 |
ROIC/WACC1.06
WACC8.4%
2.3 Liquidity
- IDP has a Current Ratio of 2.68. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
- IDP's Current ratio of 2.68 is in line compared to the rest of the industry. IDP outperforms 55.42% of its industry peers.
- IDP has a Quick Ratio of 2.03. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
- IDP has a Quick ratio (2.03) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.03 |
3. IDP.DE Growth Analysis
3.1 Past
- IDP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.16%.
- Measured over the past years, IDP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -14.17% on average per year.
- IDP shows a small growth in Revenue. In the last year, the Revenue has grown by 2.22%.
- Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -5.96% on average per year.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
3.2 Future
- IDP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.53% yearly.
- Based on estimates for the next years, IDP will show a decrease in Revenue. The Revenue will decrease by -0.48% on average per year.
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. IDP.DE Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 12.57, the valuation of IDP can be described as correct.
- Based on the Price/Earnings ratio, IDP is valued cheaply inside the industry as 91.57% of the companies are valued more expensively.
- IDP is valuated cheaply when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
- IDP is valuated reasonably with a Price/Forward Earnings ratio of 11.95.
- 97.59% of the companies in the same industry are more expensive than IDP, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.27, IDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.57 | ||
| Fwd PE | 11.95 |
4.2 Price Multiples
- IDP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IDP is cheaper than 89.16% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, IDP is valued cheaply inside the industry as 95.18% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.97 | ||
| EV/EBITDA | 8.31 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDP does not grow enough to justify the current Price/Earnings ratio.
- IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.44
PEG (5Y)N/A
EPS Next 2Y4.3%
EPS Next 3Y4.87%
5. IDP.DE Dividend Analysis
5.1 Amount
- No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IDP.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:IDP (3/11/2026, 7:00:00 PM)
165.1
+2.55 (+1.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06 2026-02-06/bmo
Earnings (Next)04-29 2026-04-29
Inst Owners97.35%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap24.23B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target177.03 (7.23%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)6.89%
PT rev (3m)13.87%
EPS NQ rev (1m)-13.19%
EPS NQ rev (3m)-11.95%
EPS NY rev (1m)5.69%
EPS NY rev (3m)4.68%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.57 | ||
| Fwd PE | 11.95 | ||
| P/S | 2.85 | ||
| P/FCF | 13.97 | ||
| P/OCF | 12.79 | ||
| P/B | 1.54 | ||
| P/tB | 10.9 | ||
| EV/EBITDA | 8.31 |
EPS(TTM)13.13
EY7.95%
EPS(NY)13.81
Fwd EY8.37%
FCF(TTM)11.82
FCFY7.16%
OCF(TTM)12.9
OCFY7.82%
SpS57.89
BVpS106.86
TBVpS15.14
PEG (NY)2.44
PEG (5Y)N/A
Graham Number177.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.39% | ||
| ROE | 7.08% | ||
| ROCE | 10.59% | ||
| ROIC | 8.93% | ||
| ROICexc | 10.46% | ||
| ROICexgc | 35.29% | ||
| OM | 27.94% | ||
| PM (TTM) | 13.07% | ||
| GM | 75.69% | ||
| FCFM | 20.42% |
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | 3.11 | ||
| Debt/EBITDA | 1.77 | ||
| Cap/Depr | 23.77% | ||
| Cap/Sales | 1.87% | ||
| Interest Coverage | 10.46 | ||
| Cash Conversion | 62.22% | ||
| Profit Quality | 156.18% | ||
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.03 | ||
| Altman-Z | 3.34 |
F-Score4
WACC8.4%
ROIC/WACC1.06
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
What is the valuation status for IDP stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
What is the financial health of BIOGEN INC (IDP.DE) stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to grow by 5.16% in the next year.